Chief Strategy and Financial Officer and Treasurer · Elicio Therapeutics, Inc. (ELTX)

Preetam Shah

FY2025 is the first fiscal year CompBrief holds for Preetam Shah as a named executive officer of Elicio Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,377,686

Salary $350,612Stock awards $0

2nd of 3 named executive officers at Elicio Therapeutics by FY2025 total.

3 named officers on file for Elicio Therapeutics, FY2025

Preetam Shah’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Elicio Therapeutics’s whole pay program stands against its peers

  • Elicio Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ELTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed October 9, 2026 (DEF 14A).

Free

Get Preetam Shah’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Preetam Shah compensation by year

Elicio Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Elicio Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$350,612
Bonus$0
Stock awards$0
Option awards$796,143
Non-equity incentive$201,600
Pension and deferred compensation$0
All other$29,331
Total$1,377,686

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Elicio Therapeutics, Inc. DEF 14A filed October 9, 2026, accession 0001601485-26-000061, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Elicio Therapeutics, Inc. filed document, accession 0001601485-26-000061. Every figure is read from that document and cited to the page and table it appears in. Filed October 9, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option191,624—$4.98

Per the Outstanding Equity Awards at Fiscal Year-End table in Elicio Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Elicio Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Robert ConnellyPresident, Chief Executive Officer, and Director$1,887,660
Preetam Shah · this pageChief Strategy and Financial Officer and Treasurer$1,377,686
Christopher HaqqExecutive Vice President, Head of Research and Development and Chief Medical Officer$1,078,176

The full Elicio Therapeutics compensation record

free company brief

This page is one person within Elicio Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Elicio Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Preetam Shah's compensation dossier · One-time report. No refunds.